Cancer Biologics Market Size, Share, Trends, Growth Outlook |2025-2034

The Global Cancer Biologics Market Size is estimated at $138.3 Billion in 2025 and is forecast to register an annual growth rate (CAGR) of 10.4% to reach $336.9 Billion by 2034.

The market growth is driven by an increasing expansion of biologic platforms beyond monoclonal antibodies (mAbs) is diversifying the landscape of cancer biologics. Novel biological platforms such as bispecific antibodies, oncolytic viruses, and adoptive cell therapies (e.g., CAR-T cell therapy) offer unique mechanisms of action and therapeutic potential in cancer treatment. These next-generation biologic platforms are undergoing clinical development and gaining regulatory approvals, contributing to the growth and innovation within the cancer biologics market. Leading Companies focusing on Expanding Therapeutic Indications, Enhanced Personalization and Biomarker Discovery, Innovative Drug Delivery Technologies, and others to boost market shares in the industry.

Cancer Biologics Market Overview

The cancer biologics market is experiencing robust growth driven by advancements in biotechnology, increasing cancer prevalence, and the shift toward targeted therapies and immunotherapy. Major pharmaceutical companies like Roche, Bristol Myers Squibb, and Merck & Co. dominate the landscape with a wide array of biologic products targeting various cancers. Monoclonal antibodies and immune checkpoint inhibitors stand out as particularly successful therapeutic modalities, revolutionizing cancer treatment. Despite challenges like high development costs and treatment resistance, ongoing research efforts and regulatory initiatives aimed at expediting drug approvals present opportunities for further innovation and improved patient outcomes in the cancer biologics market.

Cancer Biologics Market Dynamics

Cancer Biologics Market Trends- The Burgeoning Cancer Biologics Market, driven by the rise of immunotherapy, is revolutionizing cancer treatment.

The rapid expansion of the cancer biologics market, driven by the rise of immunotherapy, is fundamentally transforming cancer treatment. Immunotherapy, exemplified by immune checkpoint inhibitors and CAR-T cell therapy, has emerged as a revolutionary approach, harnessing the body's own immune defenses to target cancer cells. This paradigm shift has opened up unprecedented treatment avenues, leading to long-lasting responses and enhanced survival rates across a wide spectrum of cancers. Major pharmaceutical players are heavily investing in pioneering biologic therapies, tapping into the vast potential of immunotherapy to address previously unmet medical needs. Furthermore, the growing array of biologic drugs reflects the increasing sophistication and personalized nature of cancer care, with clinicians tailoring treatments based on individual genetic and tumor profiles. With ongoing research breakthroughs and regulatory approvals driving the momentum behind immunotherapy, the cancer biologics market is poised for sustained growth and groundbreaking innovation in the battle against cancer.

Market Driver- Biosimilars are fueling a surge in the cancer biologics market, presenting both opportunities and challenges for stakeholders.

Biosimilars are significantly influencing the growth of the cancer biologics market, presenting both opportunities and challenges for stakeholders in healthcare. These intricate biological products closely resemble approved reference biologics and offer cost-effective alternatives for cancer treatment, thereby widening patient access to vital therapies. Furthermore, biosimilars foster competition, potentially reducing overall healthcare expenses and spurring innovation. However, hurdles remain, encompassing regulatory complexities, safety and efficacy concerns, and the imperative for robust pharmacovigilance to safeguard patients. Additionally, market dynamics like pricing pressures and the necessity for effective market access strategies pose obstacles for biosimilar manufacturers aiming to penetrate the oncology sector. Despite these challenges, biosimilars show promise in reshaping the cancer biologics landscape, necessitating stakeholders to adeptly navigate complexities to leverage benefits while mitigating risks.

Market Opportunity- The cancer biologics market is revolutionizing oncology with precision medicine and personalized therapies.

The integration of precision medicine and personalized therapies into the cancer biologics market marks a transformative shift in oncology, delivering custom-tailored treatment strategies that take into account individual genetic profiles and tumor attributes. This shift enables the implementation of highly targeted interventions, reducing harm to healthy tissues while optimizing treatment effectiveness. Biomarker-driven diagnostics are instrumental in pinpointing patients who are best suited for specific biologic therapies, empowering oncologists to make well-informed decisions and enhance treatment results. Advancements in genomics, molecular profiling, and computational biology are driving the evolution of cancer care toward a patient-centric model, wherein therapy selection is guided by the distinct molecular characteristics of each tumor. This innovative approach not only enhances patient outcomes but also represents a significant advancement in the battle against cancer, ushering in a new era of hope with personalized and precise treatments tailored to meet the unique needs of each individual.

Cancer Biologics Market Share Analysis- Cell and Gene Therapy is expected to register the fastest growth rate (CAGR) over the forecast period from 2025 to 2034.

The Global Cancer Biologics Market is analyzed across Monoclonal Antibodies, Vaccines, Cell and Gene Therapy, and others. Cell and Gene Therapy is poised to register the fastest growth. Cell and gene therapy in the cancer biologics market represent groundbreaking treatment approaches, utilizing engineered immune cells and genetic modifications to precisely target and eradicate cancer cells. These innovative therapies offer highly personalized and effective solutions for various cancers, demonstrating remarkable efficacy and durable responses in clinical trials. Despite challenges like manufacturing complexities, their rapid development underscores their potential to revolutionize cancer care, providing new hope for patients with limited treatment options.

Cancer Biologics Market Share Analysis- Non-Small Cell Lung Cancer held a significant market share in 2024

The Global Cancer Biologics Market is analyzed across various applications including Non-Small Cell Lung Cancer, Prostate Cancer, Breast Cancer, Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma, Ovarian Cancer, Colorectal Cancer, Gastric Cancers, and others. Of these, Non-small Cell Lung Cancer held a significant market share in 2024. The Non-Small Cell Lung Cancer (NSCLC) segment in the cancer biologics market is experiencing notable growth, driven by rising global prevalence, advancements in biotechnology facilitating targeted therapies and immunotherapies, and increasing demand for personalized treatment options. Key players are investing in research to develop innovative biologic drugs targeting specific molecular pathways and immune checkpoints associated with NSCLC, while collaborations between industry and academia foster further innovation. Biomarker-driven diagnostics and precision medicine approaches are playing a crucial role, enabling tailored treatment regimens based on the unique molecular characteristics of NSCLC tumors, ultimately improving patient outcomes and survival rates.

Cancer Biologics Market Segmentation

By Type

• Monoclonal Antibodies
• Vaccines
• Cell And Gene Therapy
• Others

 By Application

• Non-small Cell Lung Cancer
• Prostate Cancer
• Breast Cancer
• Acute Myeloid Leukemia
• Lymphoma
• Multiple Myeloma
• Ovarian Cancer
• Colorectal Cancer
• Gastric Cancers
• Others

By Distribution Channel

• Hospitals
• Clinics
• Others

By Region

• North America (United States, Canada, Mexico)
• Europe (Germany, France, United Kingdom, Spain, Italy, Others)
• Asia Pacific (China, India, Japan, South Korea, Australia, Others)
• Latin America (Brazil, Argentina, Others)
• Middle East and Africa (Saudi Arabia, UAE, Kuwait, Other Middle East, South Africa, Nigeria, Other Africa)

Cancer Biologics Companies Profiled in the Study

• AstraZeneca Plc
• Bayer AG
• Biocon Ltd
• Biogen Inc
• Bristol Myers Squibb Co
• Celltrion Co Ltd
• Cipla Ltd
• Dr Reddys Laboratories Ltd
• Eli Lilly and Co
• F. Hoffmann La Roche Ltd
• Gilead Sciences Inc
• GlaxoSmithKline Plc
• Jazz Pharmaceuticals Plc
• Johnson and Johnson
• Lupin Ltd
• Merck KGaA
• Novartis AG
• Ono Pharmaceutical Co Ltd
• Viatris Inc

*List not exhaustive

Cancer Biologics Market Outlook 2025

1 Market Overview

1.1 Introduction to the Cancer Biologics Market

1.2 Scope of the Study

1.3 Research Objective

1.3.1 Key Market Scope and Segments

1.3.2 Players Covered

1.3.3 Years Considered

 

2 Executive Summary

2.1 2024 Cancer Biologics Industry- Market Statistics

3 Market Dynamics

3.1 Market Drivers

3.2 Market Challenges

3.3 Market Opportunities

3.4 Market Trends

 

4 Market Factor Analysis

4.1 Porter’s Five Forces

4.2 Market Entropy

4.2.1 Global Cancer Biologics Market Companies with Area Served

4.2.2 Products Offerings Global Cancer Biologics Market

 

5 Recession Impact Analysis and Outlook Scenarios

5.1.1 Recission Impact Analysis

5.1.2 Market Growth Scenario- Base Case

5.1.3 Market Growth Scenario- Reference Case

5.1.4 Market Growth Scenario- High Case

 

6 Global Cancer Biologics Market Trends

6.1 Global Cancer Biologics Revenue (USD Million) and CAGR (%) by Type (2019-2034)

6.2 Global Cancer Biologics Revenue (USD Million) and CAGR (%) by Applications (2019-2034)

6.3 Global Cancer Biologics Revenue (USD Million) and CAGR (%) by Regions (2019-2034)

 

7 Global Cancer Biologics Market Revenue (USD Million) by Type, and Applications (2019-2024)

7.1 Global Cancer Biologics Revenue (USD Million) by Type (2019-2024)

7.1.1 Global Cancer Biologics Revenue (USD Million), Market Share (%) by Type (2019-2024)

7.2 Global Cancer Biologics Revenue (USD Million) by Applications (2019-2024)

7.2.1 Global Cancer Biologics Revenue (USD Million), Market Share (%) by Applications (2019-2024)

 

8 Global Cancer Biologics Development Regional Status and Outlook

8.1 Global Cancer Biologics Revenue (USD Million) By Regions (2019-2024)

8.2 North America Cancer Biologics Revenue (USD Million) by Type, and Application (2019-2024)

8.2.1 North America Cancer Biologics Revenue (USD Million) by Country (2019-2024)

8.2.2 North America Cancer Biologics Revenue (USD Million) by Type (2019-2024)

8.2.3 North America Cancer Biologics Revenue (USD Million) by Applications (2019-2024)

8.3 Europe Cancer Biologics Revenue (USD Million), by Type, and Applications (USD Million) (2019-2024)

8.3.1 Europe Cancer Biologics Revenue (USD Million), by Country (2019-2024)

8.3.2 Europe Cancer Biologics Revenue (USD Million) by Type (2019-2024)

8.3.3 Europe Cancer Biologics Revenue (USD Million) by Applications (2019-2024)

8.4 Asia Pacific Cancer Biologics Revenue (USD Million), and Revenue (USD Million) by Type, and Applications (2019-2024)

8.4.1 Asia Pacific Cancer Biologics Revenue (USD Million) by Country (2019-2024)

8.4.2 Asia Pacific Cancer Biologics Revenue (USD Million) by Type (2019-2024)

8.4.3 Asia Pacific Cancer Biologics Revenue (USD Million) by Applications (2019-2024)

8.5 South America Cancer Biologics Revenue (USD Million), by Type, and Applications (2019-2024)

8.5.1 South America Cancer Biologics Revenue (USD Million), by Country (2019-2024)

8.5.2 South America Cancer Biologics Revenue (USD Million) by Type (2019-2024)

8.5.3 South America Cancer Biologics Revenue (USD Million) by Applications (2019-2024)

8.6 Middle East and Africa Cancer Biologics Revenue (USD Million), by Type, Technology, Application, Thickness (2019-2024)

8.6.1 Middle East and Africa Cancer Biologics Revenue (USD Million) by Country (2019-2024)

8.6.2 Middle East and Africa Cancer Biologics Revenue (USD Million) by Type (2019-2024)

8.6.3 Middle East and Africa Cancer Biologics Revenue (USD Million) by Applications (2019-2024)

 

9 Company Profiles

 

10 Global Cancer Biologics Market Revenue (USD Million), by Type, and Applications (2025-2034)

10.1 Global Cancer Biologics Revenue (USD Million) and Market Share (%) by Type (2025-2034)

10.1.1 Global Cancer Biologics Revenue (USD Million), and Market Share (%) by Type (2025-2034)

10.2 Global Cancer Biologics Revenue (USD Million) and Market Share (%) by Applications (2025-2034)

10.2.1 Global Cancer Biologics Revenue (USD Million), and Market Share (%) by Applications (2025-2034)

 

11 Global Cancer Biologics Development Regional Status and Outlook Forecast

11.1 Global Cancer Biologics Revenue (USD Million) By Regions (2025-2034)

11.2 North America Cancer Biologics Revenue (USD Million) by Type, and Applications (2025-2034)

11.2.1 North America Cancer Biologics Revenue (USD) Million by Country (2025-2034)

11.2.2 North America Cancer Biologics Revenue (USD Million), by Type (2025-2034)

11.2.3 North America Cancer Biologics Revenue (USD Million), Market Share (%) by Applications (2025-2034)

11.3 Europe Cancer Biologics Revenue (USD Million), by Type, and Applications (2025-2034)

11.3.1 Europe Cancer Biologics Revenue (USD Million), by Country (2025-2034)

11.3.2 Europe Cancer Biologics Revenue (USD Million), by Type (2025-2034)

11.3.3 Europe Cancer Biologics Revenue (USD Million), by Applications (2025-2034)

11.4 Asia Pacific Cancer Biologics Revenue (USD Million) by Type, and Applications (2025-2034)

11.4.1 Asia Pacific Cancer Biologics Revenue (USD Million), by Country (2025-2034)

11.4.2 Asia Pacific Cancer Biologics Revenue (USD Million), by Type (2025-2034)

11.4.3 Asia Pacific Cancer Biologics Revenue (USD Million), by Applications (2025-2034)

11.5 South America Cancer Biologics Revenue (USD Million), by Type, and Applications (2025-2034)

11.5.1 South America Cancer Biologics Revenue (USD Million), by Country (2025-2034)

11.5.2 South America Cancer Biologics Revenue (USD Million), by Type (2025-2034)

11.5.3 South America Cancer Biologics Revenue (USD Million), by Applications (2025-2034)

11.6 Middle East and Africa Cancer Biologics Revenue (USD Million), by Type, and Applications (2025-2034)

11.6.1 Middle East and Africa Cancer Biologics Revenue (USD Million), by region (2025-2034)

11.6.2 Middle East and Africa Cancer Biologics Revenue (USD Million), by Type (2025-2034)

11.6.3 Middle East and Africa Cancer Biologics Revenue (USD Million), by Applications (2025-2034)

 

12 Methodology and Data Sources

12.1 Methodology/Research Approach

12.1.1 Research Programs/Design

12.1.2 Market Size Estimation

12.1.3 Market Breakdown and Data Triangulation

12.2 Data Sources

12.2.1 Secondary Sources

12.2.2 Primary Sources

12.3 Disclaimer

 

List of Tables

Table 1 Market Segmentation Analysis

Table 2 Global Cancer Biologics Market Companies with Areas Served

Table 3 Products Offerings Global Cancer Biologics Market

Table 4 Low Growth Scenario Forecasts

Table 5 Reference Case Growth Scenario

Table 6 High Growth Case Scenario

Table 7 Global Cancer Biologics Revenue (USD Million) And CAGR (%) By Type (2019-2034)

Table 8 Global Cancer Biologics Revenue (USD Million) And CAGR (%) By Applications (2019-2034)

Table 9 Global Cancer Biologics Revenue (USD Million) And CAGR (%) By Regions (2019-2034)

Table 10 Global Cancer Biologics Revenue (USD Million) By Type (2019-2024)

Table 11 Global Cancer Biologics Revenue Market Share (%) By Type (2019-2024)

Table 12 Global Cancer Biologics Revenue (USD Million) By Applications (2019-2024)

Table 13 Global Cancer Biologics Revenue Market Share (%) By Applications (2019-2024)

Table 14 Global Cancer Biologics Market Revenue (USD Million) By Regions (2019-2024)

Table 15 Global Cancer Biologics Market Share (%) By Regions (2019-2024)

Table 16 North America Cancer Biologics Revenue (USD Million) By Country (2019-2024)

Table 17 North America Cancer Biologics Revenue (USD Million) By Type (2019-2024)

Table 18 North America Cancer Biologics Revenue (USD Million) By Applications (2019-2024)

Table 19 Europe Cancer Biologics Revenue (USD Million) By Country (2019-2024)

Table 20 Europe Cancer Biologics Revenue (USD Million) By Type (2019-2024)

Table 21 Europe Cancer Biologics Revenue (USD Million) By Applications (2019-2024)

Table 22 Asia Pacific Cancer Biologics Revenue (USD Million) By Country (2019-2024)

Table 23 Asia Pacific Cancer Biologics Revenue (USD Million) By Type (2019-2024)

Table 24 Asia Pacific Cancer Biologics Revenue (USD Million) By Applications (2019-2024)

Table 25 South America Cancer Biologics Revenue (USD Million) By Country (2019-2024)

Table 26 South America Cancer Biologics Revenue (USD Million) By Type (2019-2024)

Table 27 South America Cancer Biologics Revenue (USD Million) By Applications (2019-2024)

Table 28 Middle East and Africa Cancer Biologics Revenue (USD Million) By Region (2019-2024)

Table 29 Middle East and Africa Cancer Biologics Revenue (USD Million) By Type (2019-2024)

Table 30 Middle East and Africa Cancer Biologics Revenue (USD Million) By Applications (2019-2024)

Table 31 Financial Analysis

Table 32 Global Cancer Biologics Revenue (USD Million) By Type (2025-2034)

Table 33 Global Cancer Biologics Revenue Market Share (%) By Type (2025-2034)

Table 34 Global Cancer Biologics Revenue (USD Million) By Applications (2025-2034)

Table 35 Global Cancer Biologics Revenue Market Share (%) By Applications (2025-2034)

Table 36 Global Cancer Biologics Market Revenue (USD Million), And Revenue (USD Million) By Regions (2025-2034)

Table 37 North America Cancer Biologics Revenue (USD)By Country (2025-2034)

Table 38 North America Cancer Biologics Revenue (USD Million) By Type (2025-2034)

Table 39 North America Cancer Biologics Revenue (USD Million) By Applications (2025-2034)

Table 40 Europe Cancer Biologics Revenue (USD Million) By Country (2025-2034)

Table 41 Europe Cancer Biologics Revenue (USD Million) By Type (2025-2034)

Table 42 Europe Cancer Biologics Revenue (USD Million) By Applications (2025-2034)

Table 43 Asia Pacific Cancer Biologics Revenue (USD Million) By Country (2025-2034)

Table 44 Asia Pacific Cancer Biologics Revenue (USD Million) By Type (2025-2034)

Table 45 Asia Pacific Cancer Biologics Revenue (USD Million) By Applications (2025-2034)

Table 46 South America Cancer Biologics Revenue (USD Million) By Country (2025-2034)

Table 47 South America Cancer Biologics Revenue (USD Million) By Type (2025-2034)

Table 48 South America Cancer Biologics Revenue (USD Million) By Applications (2025-2034)

Table 49 Middle East and Africa Cancer Biologics Revenue (USD Million) By Region (2025-2034)

Table 50 Middle East and Africa Cancer Biologics Revenue (USD Million) By Region (2025-2034)

Table 51 Middle East and Africa Cancer Biologics Revenue (USD Million) By Type (2025-2034)

Table 52 Middle East and Africa Cancer Biologics Revenue (USD Million) By Applications (2025-2034)

Table 53 Research Programs/Design for This Report

Table 54 Key Data Information from Secondary Sources

Table 55 Key Data Information from Primary Sources

 

List of Figures

Figure 1 Market Scope

Figure 2 Porter’s Five Forces

Figure 3 Global Cancer Biologics Revenue (USD Million) By Type (2019-2024)

Figure 4 Global Cancer Biologics Revenue Market Share (%) By Type (2023)

Figure 5 Global Cancer Biologics Revenue (USD Million) By Applications (2019-2024)

Figure 6 Global Cancer Biologics Revenue Market Share (%) By Applications (2023)

Figure 7 Global Cancer Biologics Market Revenue (USD Million) By Regions (2019-2024)

Figure 8 Global Cancer Biologics Market Share (%) By Regions (2023)

Figure 9 North America Cancer Biologics Revenue (USD Million) By Country (2019-2024)

Figure 10 North America Cancer Biologics Revenue (USD Million) By Type (2019-2024)

Figure 11 North America Cancer Biologics Revenue (USD Million) By Applications (2019-2024)

Figure 12 Europe Cancer Biologics Revenue (USD Million) By Country (2019-2024)

Figure 13 Europe Cancer Biologics Revenue (USD Million) By Type (2019-2024)

Figure 14 Europe Cancer Biologics Revenue (USD Million) By Applications (2019-2024)

Figure 15 Asia Pacific Cancer Biologics Revenue (USD Million) By Country (2019-2024)

Figure 16 Asia Pacific Cancer Biologics Revenue (USD Million) By Type (2019-2024)

Figure 17 Asia Pacific Cancer Biologics Revenue (USD Million) By Applications (2019-2024)

Figure 18 South America Cancer Biologics Revenue (USD Million) By Country (2019-2024)

Figure 19 South America Cancer Biologics Revenue (USD Million) By Type (2019-2024)

Figure 20 South America Cancer Biologics Revenue (USD Million) By Applications (2019-2024)

Figure 21 Middle East and Africa Cancer Biologics Revenue (USD Million) By Region (2019-2024)

Figure 22 Middle East and Africa Cancer Biologics Revenue (USD Million) By Type (2019-2024)

Figure 23 Middle East and Africa Cancer Biologics Revenue (USD Million) By Applications (2019-2024)

Figure 24 Global Cancer Biologics Revenue (USD Million) By Type (2025-2034)

Figure 25 Global Cancer Biologics Revenue Market Share (%) By Type (2030)

Figure 26 Global Cancer Biologics Revenue (USD Million) By Applications (2025-2034)

Figure 27 Global Cancer Biologics Revenue Market Share (%) By Applications (2030)

Figure 28 Global Cancer Biologics Market Revenue (USD Million) By Regions (2025-2034)

Figure 29 North America Cancer Biologics Revenue (USD Million) By Country (2025-2034)

Figure 30 North America Cancer Biologics Revenue (USD Million) By Type (2025-2034)

Figure 31 North America Cancer Biologics Revenue (USD Million) By Applications (2025-2034)

Figure 32 Europe Cancer Biologics Revenue (USD Million) By Country (2025-2034)

Figure 33 Europe Cancer Biologics Revenue (USD Million) By Type (2025-2034)

Figure 34 Europe Cancer Biologics Revenue (USD Million) By Applications (2025-2034)

Figure 35 Asia Pacific Cancer Biologics Revenue (USD Million) By Country (2025-2034)

Figure 36 Asia Pacific Cancer Biologics Revenue (USD Million) By Type (2025-2034)

Figure 37 Asia Pacific Cancer Biologics Revenue (USD Million) By Applications (2025-2034)

Figure 38 South America Cancer Biologics Revenue (USD Million) By Country (2025-2034)

Figure 39 South America Cancer Biologics Revenue (USD Million) By Type (2025-2034)

Figure 40 South America Cancer Biologics Revenue (USD Million) By Applications (2025-2034)

Figure 41 Middle East and Africa Cancer Biologics Revenue (USD Million) By Region (2025-2034)

Figure 42 Middle East and Africa Cancer Biologics Revenue (USD Million) By Region (2025-2034)

Figure 43 Middle East and Africa Cancer Biologics Revenue (USD Million) By Type (2025-2034)

Figure 44 Middle East and Africa Cancer Biologics Revenue (USD Million) By Applications (2025-2034)

Figure 45 Bottom-Up and Top-Down Approaches for This Report

Figure 46 Data Triangulation

Cancer Biologics Market Segmentation

By Type

• Monoclonal Antibodies
• Vaccines
• Cell And Gene Therapy
• Others

 By Application

• Non-small Cell Lung Cancer
• Prostate Cancer
• Breast Cancer
• Acute Myeloid Leukemia
• Lymphoma
• Multiple Myeloma
• Ovarian Cancer
• Colorectal Cancer
• Gastric Cancers
• Others

By Distribution Channel

• Hospitals
• Clinics
• Others

By Region

• North America (United States, Canada, Mexico)
• Europe (Germany, France, United Kingdom, Spain, Italy, Others)
• Asia Pacific (China, India, Japan, South Korea, Australia, Others)
• Latin America (Brazil, Argentina, Others)
• Middle East and Africa (Saudi Arabia, UAE, Kuwait, Other Middle East, South Africa, Nigeria, Other Africa)